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The activity of NK cells is controlled by inhibitory and activating receptors. The inhibitory
receptors interact mostly with MHC class I proteins, however, inhibitory receptors such
as CD300a, which bind to non-MHC class I ligands, also exist. Recently, it was discovered
that phosphatidylserine (PS) is a ligand for CD300a and that the interaction between PS
expressed on apoptotic cells and CD300a inhibits the uptake of apoptotic cells by phago-
cytic cells. Whether PS can inhibit NK-cell activity through CD300a is unknown. Here, we
have generated specific antibodies directed against CD300a and we used these mAbs to
demonstrate that various NK-cell clones express different levels of CD300a. We further
demonstrated that both CD300a and its highly homologous molecule CD300c bind to the
tumor cells equally well and that they recognize PS and additional unknown ligand(s)
expressed by tumor cells. Finally, we showed that blocking the PS–CD300a interaction
resulted in increased NK-cell killing of tumor cells. Collectively, we demonstrate a new
tumor immune evasion mechanism that is mediated through the interaction between PS
and CD300a and we suggest that CD300c, similarly to CD300a, also interacts with PS.
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Introduction
Natural killer (NK) cells represent the third (following B and
T cells) largest lymphoid cell population in mammals [1]. The
function of NK cells occurs naturally and unlike T or B cells,
NK cells do not require sensitization for their activity, although
recent reports demonstrate that NK cells possess a certain type
of memory [2–5]. NK cells are characterized by the expression
of activating and inhibitory receptors that mediate their function
[6]. The inhibitory receptors recognize mainly MHC class I pro-
teins [7, 8], however, inhibitory receptors that interact with pro-
teins other than MHC class I, such as CD300a, also exist [9]. The
CD300a molecule contains four immune receptor tyrosine based
inhibitory motif (ITIM) sequences in its cytoplasmic domain. It
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possesses a single V-like Ig domain that is 80% similar at the
amino acid level to another family member, CD300c. However,
unlike CD300a, CD300c contains a short cytoplasmic domain that
lacks ITIM sequences and also includes a glutamic acid residue in
its transmembrane domain, suggesting an association with as yet
an undefined signalingmolecule [10–13]. Because of the high sim-
ilarity between the extracellular portion of CD300a and CD300c,
none of the commercially available antibodies that are directed
against these proteins can discriminated between them [14,15].
Until recently, the ligand(s) recognized by CD300a were
unknown, however, Nakahashi-Oda et al. [16] and Simhadri et al.
[17] recently reported that phosphatidylserine (PS) is a ligand
for CD300a. PS is a phospholipid that is ubiquitously present
in membranes; it is normally asymmetrically distributed in the
plasma membrane of mammalian cells so that essentially all of
the PS is restricted to the cytosolic surface [18]. During several
important biological processes, this asymmetry collapses and PS
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is exposed on the cell surface. For example, PS becomes external-
ized on the cell surface during activation of platelets, during the
blood coagulation cascade [19, 20], and during the early stages
of apoptosis [18, 21, 22]. The externalization of PS appears to
be the signal by which apoptotic cells are recognized and subse-
quently removed by phagocytes [23–25]. The recognition of PS
by a phagocyte cell occurs through several different mechanisms:
via direct recognition by members of the TIM family of receptors
(TIM-1, TIM-3, and TIM-4) [26–29], BAI1 [30], and Stabilin-2
[31], and via indirect recognition by soluble PS-binding
molecules including MFG-E8 [32], Gas6 [33], and protein S
[34]. Several studies have shown that in the tumor microenviron-
ment, there is a significant stress imposed on the tumor endothe-
lium by acidity, reactive oxygen species (ROS), and by transient
hypoxia, which results in the redistribution of PS to the cell sur-
face [35, 36]. Indeed, expression of PS was detected in gastric
carcinoma [37], ovarian carcinoma [38], and melanoma [39].
Here, we identified a new tumor immune evasion mechanism
that is based on the inhibition of NK-cell activity through the
CD300a–PS interaction.
Results
Specific recognition of CD300a by newly
generated mAbs
Currently, there is no mAb that is able to discriminate between
CD300a and CD300c (data not shown and [14,15]). Therefore, to
study the function of CD300a and CD300c, we generated specific
anti-CD300a and CD300c antibodies. Mice were immunized with
fusion proteins that include the extracellular portions of CD300a
and CD300c proteins fused to human IgG1 and hybridomas were
generated according to the standard techniques.
To test the mAb specificity, we stained YTS cells transfected
to express CD300a, BW cells transfected to express CD300c, and
the corresponding parental cell lines (that are negative for CD300a
and CD300c, Fig. 1A) with three hybridomas (for an unknown rea-
son, we could not obtained transfectants of YTS cells expressing
CD300c or tranfectants of BW cells expressing CD300a and, there-
fore, we screened for the expression of CD300a and CD300c on
two different cell lines). As can be seen in Figure 1A, Hybridoma 1
and Hybridoma 4 specifically recognize CD300a and not CD300c,
while Hybridoma 2 specifically recognizes CD300c.
We next stained primary bulk NK-cell cultures derived from
various donors with the different antibodies and as can be seen in
Figure 1B, while all bulk NK cells were stained with the CD300a-
specific mAbs, Hybridoma 1 and Hybridoma 4, no staining was
detected with Hybridoma 2 (Fig. 1B and data not shown). We
have therefore continued our research with the CD300a-specific
Hybridomas 1 and 4.
Anti-CD300a antibodies inhibit NK-cell killing
in redirected cytotoxicity assays
To test whether the triggering of CD300a by Hybridomas 1 and
4 will inhibit NK-cell cytotoxicity, we performed redirected killing
Figure 1. Specific recognition of CD300a
by newly generated hybridomas. (A, B)
FACS analysis of (A) BW cells, BW express-
ing CD300c, YTS ECO cells, and YTS ECO
expressing CD300a cells, and of (B) bulk
NK-cell cultures derived from two dif-
ferent donors. The various hybridomas
are indicated above the histograms. The
anti-CD300a/c antibody recognizes both
CD300a and CD300c. Staining is indi-
cated by black-line histogram and back-
ground (filled gray histogram) is the stain-
ingwith allophycocyanin-conjugated F(ab’)2
goat anti-mouse IgG only. The gating strat-
egy is shown in the left part of the figure.
Data shown are representative of one out of
three independent experiments performed.
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Figure 2. The new CD300a hybridomas inhibit redirected NK cytotoxicity. (A) Bulk NK cells and (B) YTS CD300a cells were incubated with P815
cells that were precoated with the various antibodies (indicated in the x axis). The E:T ratio was 3:1 for the bulk NK and 20:1 for the YTS CD300a
cell line. Data are shown as means percentage and ±SD of three replicates and are representative of one out of three independent experiments
performed. **p ≤ 0.02, t-test.
assays (Fig. 2). Primary bulk NK cells (Fig. 2A) or YTS CD300a
cells (Fig. 2B) were incubated with P815 cells that were pre-
coated with and without anti-NKG2D mAb (Fig. 2A) and anti-
2B4 (Fig. 2B), in the presence or absence of the Hybridoma 1,
Hybridoma 4, Hybridoma that recognizes both CD300a and
CD300c (anti-CD300a/c, CMRF02.6 [15]), and anti-CD99 mAb
(which was used as a negative control). Basal killing of P815 cells
was observed with both the primary bulk NK cultures and the
YTS CD300a cells (the identity of the killer receptor(s) involved
in the killing of P815 cells by NK cells or by YTS is unknown),
and this basal killing was inhibited by all anti-CD300a antibod-
ies (Fig. 2); the two specific ones, Hybridomas 1 and 4, and
the anti-CD300a/c mAb. Furthermore, the NKG2D-mediated redi-
rected killing of the bulk NK-cell cultures was inhibited by all anti-
CD300a and anti-CD300a/c antibodies (Fig. 2A). Similar results
were obtained when the redirected killing of the bulk NK-cell
cultures was induced by other antibodies such as anti-CD16 and
anti-2B4 (data not shown).
The killing of the YTS cell line is executed mainly by the 2B4
receptor [40] and as can be seen in Figure 2B, the 2B4-mediated
redirected killing of YTS CD300a cells was also inhibited by all
antibodies apart from the control anti-CD99 mAb.
Human NK-cell clones express various levels
of CD300a
To study the clonal distribution of CD300a, we grew NK clones
derived from four different donors at various time points over
a period of 1 year (between 25 and 48 NK-cell clones were
obtained from each donor, Fig. 3A). The different NK clones
expressed CD300a at various levels and we thus divided them into
C© 2013 The Authors. European Journal of Immunology published by
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Figure 3. CD300a exhibits clonal pattern of expression on different NK-cell clones. (A) Schematic representation of the experimental procedure.
(B) Representative staining of the low (dark gray line histogram), medium (black line histogram), and high (light gray line histogram) clones from
each donor. Background (filled gray histogram) is the staining with allophycocyanin-conjugated F(ab’)2 goat anti-mouse IgG only.
Table 1. Three levels of expression of CD300a on NK cellsa)
Level of expression High (%) Medium (%) Low (%)
Donor 1 36.67 10 53.33
Donor 1 10.42 52.08 37.5
Donor 1 44.44 48.15 7.41
Donor 1 85.71 10.71 3.57
Donor 2 6.98 34.88 58.14
Donor 2 22.22 66.67 11.11
Donor 3 54.17 31.25 14.58
Donor 3 19.05 57.14 23.81
Donor 4 13.04 58.7 28.26
Donor 4 18.18 72.73 9.09
a)Summary of the percentages of clones expressing CD300a derived
from four different donors at various time points during a 1-year
period. NK-cell clones were divided into three groups based on the
levels of CD300a expression.
three groups based on the levels of CD300a expression (Fig. 3A).
NK-cell clones expressing CD300a at levels below MFI of 200 were
considered low expressing, clones expressing CD300a in MFI of
200–300 were considered medium, and clones expressing CD300a
in MFI higher than 300 were considered high. The percentages of
NK-cell clones in each group are indicated in Table 1 and exam-
ples of the expression of CD300a on the various clones are shown
in Figure 3B.
As can be seen in Table 1, the expression of CD300a varies sig-
nificantly among different donors. For example, 13.04 and 18.18%
of the NK-cell clones of donor 4 (NK cells from this donor were
isolated at two time points during the 1-year period of this study)
expressed CD300a at high levels, while at same time point 54.17%
of NK cells derived from donor 3 and 85% of NK cells derived from
donor 1 expressed CD300a at high levels.
Furthermore, even within the same donor the expression levels
of CD300a vary significantly, depending on the time in which they
were isolated. For example, at some point, 85.71% of donor 1 NK
cells expressed CD300a at high levels while in other time point
only 10.42% of the NK-cell clones of donor 1 expressed CD300a
at high levels (Table 1).
Tumor cells express a trypsin-sensitive ligand
for CD300
A single nucleotide polymorphism in CD300a that encodes for a
nonsynonymous mutation in the IgV-like domain (the correspond-
ing amino acids are either argenin (R) or glutamine (Q)) has
been linked to susceptibility to psoriasis [17,41]. To test whether
CD300a variants having either R94 or Q94 in CD300a will be
differentially recognized by Hybridomas 1 and 4, we constructed
fusion proteins in which the extracellular portion of CD300a con-
taining either R (CD300a R94 Ig) or Q (CD300a Q94 Ig) was fused
to human IgG1. These fusion proteins were used in ELISA assays
for recognition by the different anti-CD300a Hybridomas. As can
be seen in Figure 4A, all mAbs tested, hybridomas 1 and 4, and
the anti-CD300a/c antibody, recognized the CD300a R94 Ig and
CD300a Q94 Ig proteins equally well. CD300c Ig was recognized
by the anti-CD300a/c mAb only, whereas the control D1 Ig fusion
protein was not recognized by any of the mAb tested (Fig. 4A).
It was shown recently that PS is a ligand for CD300a [16].
To test whether tumor cells such as RKO, 293T, and 8866 cells,
which serves as targets for NK cells, express a ligand for CD300a
and CD300c, we stained them with the two CD300a fusion pro-
teins (containing either R94 or Q94), with CD300c Ig, and with
the control D1 Ig. The adherent cells RKO and 293T were har-
vested with and without trypsin. As can be seen in Figure 4B, both
adherent cells expressed a ligand for CD300a (as they were rec-
ognized by CD300a Ig containing R94 or Q94) and CD300c (since
they were recognized by CD300c Ig), whereas the nonadherent
cells 8866 did not express ligand(s) for these receptors. Interest-
ingly, following trypsin treatment the expression of the CD300a/c
ligand(s) was significantly reduced (Fig. 4B).
It was demonstrated that the binding of CD300a to PS is cal-
cium dependent [17]. Therefore, we incubated the various tumors
indicated in Figure 4C in medium with and without calcium and
observed an enhancement in the binding of all fusion proteins
except from the control Ig fusion protein, D1 Ig. The binding of
CD300a R94 Ig and CD300a Q94 Ig to tumor cells was very sim-
ilar, almost identical (Fig. 4D), regardless of whether the cells
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Figure 4. Tumor cells express a trypsin sensitive ligand for CD300. (A) Fusion proteins (indicated in the x axis) were incubated on ELISA plates
and ELISA assays were performed with the indicated mAbs. Data are shown as means and ±SD of three replicates and are representative of one
out of three independent experiments performed. **p ≤ 0.004, ***p ≤ 0.001, t-test. (B) 8866, RKO, and 293T cells were harvested with or without
trypsin (black and gray line histogram, respectively) and FACS staining was performed. Background (filled gray histogram) is the staining with
allophycocyanin-conjugated F(ab’)2 goat anti-human IgG only. (C) The various tumor cells indicated in the figure were harvested without trypsin
and treated with medium with or without calcium (black and gray open histograms, respectively). Background (filled gray histogram) is the
staining with allophycocyanin-conjugated F(ab’)2 goat anti-human IgG only. (D) Binding of CD300a R94 Ig and CD300a Q94 Ig (black and gray open
histogram, respectively) to various tumor cell lines. (E) Binding of CD300a Ig and CD300c Ig (black and gray open histogram, respectively) to various
tumor cell lines. (B–D) Data shown are representative of one out of three independent experiments performed.
were treated with or without trypsin and with or without calcium.
Interestingly, the binding of CD300c was also very similar to that
of CD300a (Fig. 4E) and it remained similar in the presence or in
the absence of the various treatments.
Tumor cells express PS
As previous reports have shown that PS is a ligand for CD300a
[16, 17], we next tested whether PS is expressed by tumor cells
and as can be seen in Figure 5, it is indeed expressed by both adher-
ent (Fig. 5A) and nonadherent cells (Fig. 5B). The expression of
PS is variable and some adherent cells express PS at low levels,
while others express PS at high levels (Fig. 5A). A similar picture
is observed with regard to the nonadherent cells (Fig. 5B). Fur-
thermore, some mouse cells (such as RMAS, EL4, and PD1.6) also
express PS, while others (such as YAC1) are PS negative (Fig. 5B).
All cells that express PS at high levels were recognized by CD300a
Ig and CD300c Ig (data not shown).
Since we have demonstrated above that the expression of
the tumor ligand(s) for CD300a is trypsin-sensitive and calcium-
dependent, we have next tested whether the expression of PS
will be influenced by these treatments. Adherent cells were har-
vest with or without trypsin and as can be seen in Figure 5A, the
levels of PSwere significantly reduced following trypsin treatment.
The calcium treatment did not affect the expression of PS either
on the adherent cells (Fig. 5A) or on the nonadherent cells (data
not shown), suggesting that calcium is probably important for the
CD300a and CD300c binding to PS and not for the expression of
PS itself.
PI-negative tumor cells are recognized by CD300a
and CD300c
It was reported that PS is expressed on dying cells and that it
inhibits the engulfment of the apoptotic cells by macrophages
[17]. To test whether the tumor cells that are recognized by
CD300a are apoptotic, we double stained the tumor cells with anti-
PS and with propidium iodide (PI). As can be seen in Figure 6A,
both 293T and RKO cells lines express PS and are recognized by
CD300a Ig, however, most of the cells were PI negative, indicating
C© 2013 The Authors. European Journal of Immunology published by
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Figure 5. Tumor cell lines express phosphatidylserine
(PS). Various tumor cell lines, (A) adherent and (B) non-
adherent were stained with anti-PS antibody. (A) The
adherent cells were harvested with or without trypsin
and incubated with medium with or without calcium.
The MFI average of three independent experiments is
shown as means and ± SD. *p ≤ 0.01, t-test.
that these cells are not found in a late apoptotic stage. The 8866
cell line that was not recognized by CD300a Ig did not express
PS (Fig. 6A). Thus, we concluded that either 293T and RKO are
always a bit apoptotic or that alternatively PS is expressed by these
tumor cells naturally, regardless of their apoptotic status.
Another reason accounting for the expression of PS on RKO
and 293T cells might be that the anti-PS antibody we used is not
specific to PS only. Therefore, we confirmed the PS expression on
the tumor cells by using annexin V. As can be seen in Figure 6B, PS
is indeed expressed by RKO and 293T cells as they were stained
by annexin V, while 8866 cells were negative.
We showed above (Fig. 4 and 5) that the binding of the anti-PS
mAb to the tumor cells was reduced by trypsin treatment. There-
fore, we treated the tumor cells with trypsin, stained them with
annexin V, and observed that the annexin V binding was reduced
upon trypsin treatment (Fig. 6B, right). The 8866 cells were some-
times recognized by annexin V (Fig. 6B, right). However, because
the 8866 cells were never recognized by the anti-PS antibody and
the annexin V staining was not reduced following trypsin treat-
ment (Fig. 6B, right), we considered this binding to 8866 cells
nonspecific.
To further study the CD300a Ig and CD300c Ig binding to tumor
cells, we next performed double staining of the tumor cells with
PS together with CD300a Ig and CD300c Ig. As can be seen in
Figure 6C, most of the PS-positive cells were recognized by
CD300a and CD300c Ig. However, staining of CD300a Ig and
CD300c Ig was detected also in a subset of PS-negative cells (espe-
cially in RKO, Fig. 6C), suggesting that CD300a and CD300c recog-
nize additional ligand(s) other than PS that are expressed on RKO
and 293T cells. Finally, we showed that the RKO and 293T cells
that were recognized by CD300a and CD300c Ig are not found in
the late apoptotic stage as they were almost entirely PI-negative
(Fig. 6D).
To demonstrate directly that CD300a Ig and CD300c Ig
interact with PS, we blocked the PS recognition by using
MGF-E8 that was previously shown to block the CD300a–PS
interaction on macrophages [16, 32]. Importantly, following
incubation of RKO and 293T cells with MGF-E8, the binding of
CD300a Ig and CD300c Ig was reduced (Fig. 6E), indicating that
both proteins interact with PS. When RKO and 293T cells were
treated with trypsin, the binding of CD300a Ig and CD300c Ig was
reduced but still detected and this binding could not be blocked
with MGF-E8 (Fig. 6E). No binding of CD300a Ig or CD300c Ig
was detected to 8866 cells in the presence or absence of MGF-E8,
with or without trypsin (Fig. 6E). Thus, we concluded that both
CD300a and CD300c recognize two different ligands on RKO and
293T cells: (i) a trypsin-sensitive ligand PS and (ii) a trypsin-
insensitive unknown ligand.
Blocking of PS enhanced the killing of tumor cells
by NK cells
We next performed NK-cell cytotoxicity assays. Because both
anti-CD300a mAbs that we have generated (Hybridoma 1 and
C© 2013 The Authors. European Journal of Immunology published by
WILEY-VCH Verlag GmbH & Co. KGaA Weinheim.
www.eji-journal.eu
Eur. J. Immunol. 2013. 43: 2151–2161 Innate immunity 2157
Hybridoma 4) are not blocking antibodies (data not shown), we
blocked the interaction of CD300a with PS by using MGF-E8. As
can be seen in Figure 7A, when PS was blocked, the killing of the
cells expressing PS (RKO and 293T) was significantly enhanced,
while the killing of the PS-negative cell line, 8866, remained
unchanged, suggesting that the interactions between CD300a and
PS indeed inhibit NK-cell cytotoxicity.
The enhancement of NK-cell killing following MGF-E8 block-
ing can result from the interaction of PS with receptors other
than CD300a that are present on human NK cells. Therefore, to
demonstrate directly that the interaction between CD300a and
PS inhibits tumor cell killing, we used the YTS cell line. As men-
tioned above, the killing of target cells by YTS cells is mediated
via the 2B4–CD48 interactions. Because both RKO and 293T cells
are CD48 negative (Fig. 7B), we expressed the CD48 protein in
293T cells and verified that the expression of PS was similar to the
parental 293T cells (Fig. 7B). Next, we performed killing assays
using YTS cells and the various 293T cells in the presence and
absence of MGF-E8. As can be seen in Figure 7C, in the absence of
CD48, the parental 293T cells were not killed by YTS cells. In con-
trast, a moderate killing was executed by the parental YTS ECO
cells against 293T CD48 cells and this moderate killing was sig-
nificantly reduced when YTS CD300a were used. Importantly, the
reduction in YTS CD300a killing was partially dependent on PS as
incubation of 293T CD48 cells with MGF-E8 partially restored the
killing by YTS CD300a cells (Fig. 7C).
Discussion
The CD300 family consists of seven protein members that coor-
dinate leukocyte responses [42]. Members of the human CD300
family have broad expression patterns and the function of the
various members is largely unknown [43].
We started this research by generating two specific anti-
CD300a antibodies and one specific mAb against CD300c. The
anti-CD300c mAb specifically recognized the CD300c-Ig fusion
 Figure 6. CD300a and CD300c interact with phosphatidylserine (PS)
expressed by tumor cell lines. (A) The indicated tumor cells were double
stained with PI and PS (left). Values in quadrants indicate percentages.
FACS analysis of the indicated different tumor cell lines harvested with
or without trypsin (black and gray open histogram, respectively) and
stained with anti-PS mAb (right histograms). Background (filled gray
histogram) is the stainingwith allophycocyanin-conjugated F(ab’)2 goat
anti-mouse IgG only. (B) The indicated tumor cells were double stained
with PI and with annexin V (left). Values in quadrants indicate percent-
ages. FACS analysis of the indicated tumor cell lines harvested with
or without trypsin (black and gray open histogram, respectively) and
stained with annexin V (right). (C, D) The various tumor cells indicated
in the figure were double stained with anti-PS (C) or PI (D) together
with the indicated fusion proteins. The numbers in the figure indicate
percentages. (E) The various tumor cells (each tumor cell line is repre-
sented by two histogram rows) were treated without trypsin (−, upper
histogram row in each tumor cell line) or with trypsin (+, lower his-
togram row in each tumor cell line), incubated with or without 0.5 μg
MGF-E8 (black and gray open histogram, respectively), and then incu-
bated with the indicated fusion protein. Data shown are representative
of one out of three independent experiments performed.
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Figure 7. Blocking of phosphatidylserine (PS) enhance the killing of tumor cells by NK cells. (A) The indicated cells were incubated with or without
0.5 μg per well of MGF-E8 and then incubated with bulk NK-cell cultures at different E:T ratios. **p ≤ 0.01, ***p ≤ 0.0006, t-test. (B) 293T and 293T
CD48 were stained with anti-CD48 and anti-PS antibody (indicated above the histograms). The black line histogram represents the staining with
the appropriate mAb, while the gray filled histogram is the background staining with allophycocyanin-conjugated F(ab’)2 goat anti-mouse IgG
only. The gating strategy is shown in the left part of the figure. (C) The parental YTS ECO cells and YTS CD300a cells were incubated with 293T or
293T CD48 in the presence or absence of 1 μg MGF-E8. The E:T ratio was 20:1. *p ≤ 0.05, **p ≤ 0.04, ***p ≤ 0.008, t-test. Data are shown as means
percentage and ±SD of three replicate and are representative of one out of three independent experiments performed.
and transfectants expressing CD300c, however, it did not recog-
nize CD300c on NK cells. One possible explanation for discrepancy
is that on the surface of the NK cells the epitope that is recognized
by our anti-CD300c mAb is masked by another protein, maybe the
one that is associated with it charged amino acid that is present
in the transmembrane domain of the receptor.
We showed that NK cells can be divided into three groups
based on the levels of CD300a expression, and that the percent-
ages of such clones vary significantly among various individuals
and even when the NK cells are taken from the same donor at
various time points (the NK-cell clones were grown during the
study period using the exact same conditions and staining were
performed at exactly the same time following NK-cell isolation).
It is possible that the levels of CD300a expression on the different
NK clones might result from different cloning efficiencies. It will
be interesting to characterize in the future the expression pattern
of CD300a on NK cells derived from various tissues, such as lymph
nodes, lungs, decidua, and liver, and to test which factors affect
the levels of expression of CD300a.
Only recently, it was found that PS interacts with CD300a
and that this leads to inhibition of phagocytosis of apoptotic cells
[17]. Our data support the above observations that the binding of
CD300a-Ig to tumor cells is reduced when PS is blocked and that
the blocking of PS enhances NK-cell-mediated cytotoxicity. Block-
ing of PS only partially blocked the binding of CD300a to tumor
cells and only partially restored NK-cell cytotoxicity, indicating
that tumor cells express an additional ligand for CD300a. Further-
more, we showed that the other ligand for CD300a expressed on
tumor cells have different biochemical properties than that of PS
as it was trypsin insensitive.
This additional ligand might be phosphatidylethanolamine
(PE) that was also shown to be a ligand for CD300a [17]. We
have tried to investigate this option and to study the function of PE
with regard to NK-cell activity. Because antibodies against PE are
unavailable, we used durmycin to block the PE interactions with
CD300a; however, unfortunately, the drug was toxic to the cells.
The realization that CD300a present on NK cells interacts with
PS might help in the discovery of new functions and interactions
C© 2013 The Authors. European Journal of Immunology published by
WILEY-VCH Verlag GmbH & Co. KGaA Weinheim.
www.eji-journal.eu
Eur. J. Immunol. 2013. 43: 2151–2161 Innate immunity 2159
between NK cells and other cells. For example, bone marrow cells
express high levels of PS as a part of the bone assembling and
disassembling processes [44]. PS also plays a major role in coag-
ulation and platelets express high level of PS following activation
[18,45].
We demonstrated here that tumor cell lines are protected
from NK-cell-mediated cytotoxicity via the CD300a–PS interac-
tions and that PI-negative tumor cells express PS. Our results are
supported by previous findings showing that tumor cells exhibit
elevated expression of PS in the outer leaflet of the cell membrane
[37,46,47].
The CD300a protein has two isoforms (R94 and Q94) and we
showed here that the tumor ligand(s) for CD300a and CD300c is
recognized equally well by both CD300a isoforms and by CD300c.
In contrast, Simhadri et al. [17] demonstrated that CD300a R94
isoform binds PS at a higher affinity than that of the Q94 iso-
form. We think that the reasons for these differences are derived
from the different systems used to evaluate the binding of the
various isoforms. Simhadri et al. used primarily surface plasmon
resonance (SPR) analysis and ELISA in which PS- and PE-
containing liposomes were used and we have used cell culture sys-
tems. Indeed, when the CD300a isoforms were used by Simhadri
et al. to stain dead PBLs, the differences were minor [17].
We further showed that the tumor ligand(s) for CD300a and
also CD300c are sensitive to trypsin and since PS is a lipid, we
wondered why it is influenced by the trypsin proteases.
Membrane lipid sidedness originates from vectorial biosynthe-
sis of lipids in combination with transporter proteins that move
lipids from one side of the membrane to the other [48,49]. Thus,
if PS is found on the cell membrane attached to these chaperons,
it will be trypsin sensitive. Indeed, several studies reported on
a connection between membrane proteins and PS. For example,
a link between glycophorin-C binding (ligation) and PS expres-
sion on erythrocytes has been suggested by its appearance on
Plasmodium falciparum infected erythrocytes [50]. In addition, it
was shown that human gastric carcinoma cells that overexpress
BCRP (an ABC transporter) also overexpress PS and that treating
these cells with tryprostatin A decreased the expression of PS [37].
We demonstrated here that CD300c has binding properties
similar to CD300a: the CD300c binding to tumor cells was trypsin-
sensitive and calcium-dependent, the binding was correlated with
expression of PS and in all cases the intensity of CD300c binding
was almost identical to that of CD300a. Finally, we demonstrated
that treating the tumor cells with MGF-E8 diminished the binding
of CD300c Ig. Thus, we suggest that, by similarly to CD300a,
CD300c also interacts with PS.
Materials and methods
Ethics statement
The NK cells that were used in this study were obtained from the
blood of healthy voluntaries. The intuitional Helsinki committee of
Hadassah approved the study (Helsinki number 0030-12-HMO).
All subjects provided a written informed consent.
Reagents, mAbs, and cells
The anti-CD300a: Hybridoma 1 and Hybridoma 4; anti-CD300a/c
(CMRF2.06); and anti-CD300c: Hybridoma 2 were generated
using standard protocols through the injection of CD300a-Ig and
CD300c-Ig fusion proteins into mice. The following reagents were
used: anti Phosphatidylserine (Millipore, clone 1H6) annexin
V-FITC (IQ Products) and Milk fat globule EGF factor 8
(MGF-E8, R&D systems). The cell lines used in the present study
were the mouse BW cells, BW transfected with CD300c, and YTS
cells, transfectedwith either the ecotropicmurine retrovirus recep-
tor alone (YTS ECO) or with the ecotropic receptor and CD300a
(YTS CD300a) [15, 51]. Additional tumor cell lines used in the
present study were RKO, 293T, and 8866.
Ig-fusion proteins
The following Ig fusion proteins CD300a R94-Ig, CD300a Q94-
Ig CD300c-Ig, and D1-Ig were generated as described previously
[15]. The CD300a R94 isoform was cloned from the CIR cell line
cDNA and CD300a Q94 isoform was cloned from bulk NK-cell
cDNA.
Cytotoxicity assays
For the redirected killing assay, bulk NK or YTS cells were added
to 35S-labeled P815 cells that were precoated with 0.2 μg per well
of the various mAbs. The level of cytotoxicity was determined as
previously described [52]. The cytotoxic activity of primary NK
cells against the various targets were assessed in 5 h 35S release
assays, as previously described. To block the PS–CD300a interac-
tion, tumor cells were incubated with or without 0.5–1 μg per well
of MFG-E8 (R&D Systems) for 30 min at RT and then incubated
with the bulk NK or with YTS cells.
Flow cytometry of tumor cells
Flow cytometry assays were performed as previously described
[15]. Cells were harvestedwith orwithout trypsin and treatedwith
or without calcium. Cells were incubated with calcium-containing
solution (10 mM N-2-hydroxyethylpiperazine-N′-2-ethanesulfonic
acid (HEPES) pH 7.4, 140 mM NaCl, 2.5 mM CaCl2, and 2 mM
MgCl2) at RT for 15 min and then washed. Blocking with MGF-E8
was performed as followed: cells were incubated with 0.5 μg per
well MGF-E8 for 30 min at RT. Next, cells were incubated with
0.3 μg of fusion proteins for 30 min at RT, washed, and stained
with a secondary allophycocyanin-conjugated F(ab′)2 goat anti-
human antibodies (Jackson Immunoresearch Laboratories). Anal-
ysis of annexin V (IQ products) binding was performed according
to manufacture instructions.
C© 2013 The Authors. European Journal of Immunology published by
WILEY-VCH Verlag GmbH & Co. KGaA Weinheim.
www.eji-journal.eu
2160 Dikla Lankry et al. Eur. J. Immunol. 2013. 43: 2151–2161
Statistical analysis
t-test was used for the statistical analysis.
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